Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in japanese subjects: A randomized two-way crossover study

Journal of International Medical Research

Volumn 38, Issue 4, 2010, Pages 1473-1483

  Furuta, K ^a   Adachi, K ^a   Ohara, S ^a   Morita, T ^a   Tanimura, T ^a   Koshino, K ^a   Kinoshita, Y ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

CYP2C19; Genotype; Intragastric pH; Japanese subjects; Omeprazole; Proton pump inhibitor; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME METABOLISM; FEMALE; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; PH MEASUREMENT; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH;

EID: 77957746915     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800430     Document Type: Article

References (38)

1. Mishima I, Adachi K, Arima N, et al: Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol 2005; 40: 1005-1009.
2. Manabe N, Haruma K, Mihara M, et al: The increasing incidence of reflux esophagitis during the past 20 years in Japan. Gastroenterology 1999; 116: A244 [abstract].
3. Azumi T, Adachi K, Arima N, et al: Five-year follow-up study of patients with reflux symptoms and reflux esophagitis in annual medical check-up field. Intern Med 2008; 47: 691-696.
4. Dimenäs E, Carlsson G, Glise H, et al: Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221: 8-13.
5. Irvine EJ: Quality of life assessment in gastrooesophageal reflux disease. Gut 2004; 53(suppl 4): iv35-iv39.
6. Hongo M, Kinoshita Y, Miwa H, et al: The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study. J Gastroenterol 2008; 43: 920-927.
7. Kinoshita Y, Ashida K, Miwa H, et al: The impact of lifestyle modification on the health-related quality of life of patients with reflux esophagitis receiving treatment with a proton pump inhibitor. Am J Gastroenterol 2009; 104: 1106-1011.
8. +)ATPase. Nature 1981; 290: 159-161.
9. + ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305.
10. DeVault KR, Castell DO, For the American College of Gastroenterology: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.
11. Labenz J, Malfertheiner P: Treatment of uncomplicated reflux disease. World J Gastroenterol 2005; 11: 4291-4299.
12. Kahrilas PJ, Shaheen NJ, Vaezi MF, For the Clinical Practice and Quality Management Committee of the American Gastroenterological Association Institute: American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1392-1413.
13. Andersson T, Regårdh CG, Lou YC, et al: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25-31.
14. Chang M, Tybring G, Dahl ML, et al: Interphenotype differences in disposition and effect on gastrin levels of omeprazole -suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-518.
15. Furuta T, Ohashi K, Kosuge K, et al: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-561.
16. Pearce RE, Rodrigues AD, Goldstein JA, et al: Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805-816.
17. Andersson T, Miners JO, Veronese ME, et al: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597-604.
18. Pichard L, Gillet G, Bonfils C, et al: Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23: 1253-1262.
19. Adachi K, Katsube T, Kawamura A, et al: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-1266.
20. Williams MP, Sercombe J, Hamilton MI, et al: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-1089.
21. +-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 1990; 39: 661-667.
22. Besancon M, Simon A, Sachs G, et al: Sites of reaction of the gastric H,K-ATPase with extra-cytoplasmic thiol reagents. J Biol Chem 1997; 272: 22438-22446.
23. Adachi K, Hashimoto T, Hamamoto N, et al: Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 2003; 18: 1392-1398.
24. De Morais SM, Wilkinson GR, Blaisdell J, et al: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
25. Kubota T, Chiba K, Ishizaki T: Genotyping of Smephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-666.
26. Guerreiro AS, Neves BC, Quina MG: Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4: 309-313.
27. Pipkin GA, Mills JG: Onset of action of anti-secretory drugs: beneficial effects of a rapid increase in intragastric pH in acid reflux disease. Scand J Gastroenterol Suppl 1999; 230: 3-8.
28. Hongo M, Kinoshita Y, Miwa H, et al: Characteristics affecting health-related quality of life (HRQOL) in Japanese patients with reflux oesophagitis and the effect of lansoprazole on HRQOL. J Med Econ 2009; 12: 182-191.
29. Pantoflickova D, Dorta G, Ravic M, et al: Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-1514.
30. Shirai N, Furuta T, Moriyama Y, et al: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-1937.
31. Sagar M, Tybring G, Dahl ML, et al: Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000; 119: 670-676.
32. Kimura M, Ieiri I, Mamiya K, et al: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998; 20: 243-247.
33. Ishizaki T, Sohn DR, Kobayashi K, et al: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994; 16: 214-215.
34. Ohkusa T, Maekawa T, Arakawa T, et al: Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther 2005; 21: 1331-1339.
35. Yamada S, Onda M, Kato S, et al: Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 2001; 36: 669-672.
36. Xie HG, Stein CM, Kim RB, et al: Allelic, genotypic and phenotypic distributions of Smephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9: 539-549.
37. Inamori M, Togawa J, Takahashi K, et al: Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J Gastroenterol Hepatol 2003; 18: 1034-1038.
38. Saitoh T, Fukushima Y, Otsuka H, et al: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16: 1811-1817.